Whereafter, IC50 assay was performed to screen the potential anti-DLBCL drugs, and among the 10 candidates, lanatoside C (LC) appealed to us because of its low IC50 in DLBCL cells and high affinity for ZDHHC21, as exhibited by molecular docking results (Supplementary Fig. 4B, C). This evidence concerns the gene ZDHHC21 and diffuse large B-cell lymphoma.